Geneva, April 20 -- International Clinical Trials Registry received information related to the study (ChiCTR2600121738) titled 'A Phase II Prospective Clinical Study of Adebrelimab combined with Chemotherapy as First-Line Treatment for Advanced Non-Small Cell Lung Cancer Complicated with Chronic Obstructive Pulmonary Disease' on April 2.
Study Type: Interventional study
Study Design:
Non randomized control
Primary Sponsor: inling Hospital, Affiliated Hospital of Medical School, Nanjing University
Condition:
Advanced Non-Small Cell Lung Cancer
Intervention:
Experimental group:Monotherapy Group: COPD patients with GOLD grade 3 who meet the inclusion criteria will receive adebrelimab 20 mg/kg by intravenous infusion every 3 weeks (Q3...